33464-71-0
Chemical Structure
Tracheloside
- CAS. Nr.: 33464-71-0
- Formula:C27H34O12
- Molecular Weight:550.55
IUPAC Name: (3S,4S)-4-(3,4-dimethoxybenzyl)-3-hydroxy-3-(3-methoxy-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzyl)dihydrofuran-2(3H)-one
InChIKey: LWYAMIUSVGPFKS-CGLYQLBNSA-N
SMILES: O=C1OC[C@H](CC2=CC=C(OC)C(OC)=C2)[C@]1(CC3=CC=C(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(OC)=C3)O
Biological Activity: Tracheloside is an orally active anticancer agent. Tracheloside can be extracted from Trachelospermum jasminoides. Tracheloside blocks TMEM16A currents, inhibits TMEM16B, and does not inhibit Bestrophin or CFTR. Tracheloside activates AMPK, inhibits NOX4, reduces Smad3 phosphorylation/nuclear translocation, and promotes YAP1 phosphorylation/degradation. Tracheloside reduces ROS/NO production, iNOS, IL-17, JNK/p38 MAPK, MMP-2/9, Bcl-2/Bcl-xL, and cyclin D1/CDK4, while increasing Nrf2, Bax, p16, Apoptosis, and cell cycle arrest. Tracheloside can be used for research on colorectal cancer, pulmonary fibrosis, full-thickness excisional wounds, lung adenocarcinoma, and rheumatoid arthritis[1][2][3][4][5][6][7][8].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tracheloside | 99.91% | Tracheloside is an orally active anticancer agent. Tracheloside can be extracted from Trachelospermum jasminoides. Tracheloside blocks TMEM16A currents, inhibits TMEM16B, and does not inhibit Bestrophin or CFTR. Tracheloside activates AMPK, inhibits NOX4, reduces Smad3 phosphorylation/nuclear translocation, and promotes YAP1 phosphorylation/degradation. Tracheloside reduces ROS/NO production, iNOS, IL-17, JNK/p38 MAPK, MMP-2/9, Bcl-2/Bcl-xL, and cyclin D1/CDK4, while increasing Nrf2, Bax, p16, Apoptosis, and cell cycle arrest. Tracheloside can be used for research on colorectal cancer, pulmonary fibrosis, full-thickness excisional wounds, lung adenocarcinoma, and rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tracheloside (Standard) | ≥98% | Tracheloside (Standard) is the analytical standard of Tracheloside (HY-N1507). This product is intended for research and analytical applications. Tracheloside is an orally active anticancer agent. Tracheloside can be extracted from Trachelospermum jasminoides. Tracheloside blocks TMEM16A currents, inhibits TMEM16B, and does not inhibit Bestrophin or CFTR. Tracheloside activates AMPK, inhibits NOX4, reduces Smad3 phosphorylation/nuclear translocation, and promotes YAP1 phosphorylation/degradation. Tracheloside reduces ROS/NO production, iNOS, IL-17, JNK/p38 MAPK, MMP-2/9, Bcl-2/Bcl-xL, and cyclin D1/CDK4, while increasing Nrf2, Bax, p16, Apoptosis, and cell cycle arrest. Tracheloside can be used for research on colorectal cancer, pulmonary fibrosis, full-thickness excisional wounds, lung adenocarcinoma, and rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.92
HY-N4276Nortracheloside -
Similarity Score 0.88
HY-N119915-Methoxytracheloside -
Similarity Score 0.84
HY-N11542Trachelogenin 4′-O-β-gentiobioside -
Similarity Score 0.81
HY-N0034Arctiin -
Similarity Score 0.81
HY-N4101Styraxlignolide F -
Similarity Score 0.79
HY-N11990Nortrachelogenin 4'-O-β-gentiobioside -
Similarity Score 0.77
HY-N11660weak Hepatoprotective agent-1 -
Similarity Score 0.76
HY-1337204-Demethyltraxillaside -
Similarity Score 0.76
HY-N17512Matairesinol-4'-O-glucoside -
Explore the MedChemAI to find more analogs
References
- [1]. Shin MK, et al. In vivo and in vitro effects of tracheloside on colorectal cancer cell proliferation and metastasis. Antioxidants. 2021 Mar 25;10(4):513.
- [2]. Li S, et al. AMPK regulates the anti-pulmonary fibrosis effects of tracheloside. Chinese Journal of Natural Medicines. 2025 Dec 1;23(12):100005.
- [3]. Shin HS, et al. Enhancing Effect of Trachelogenin from Trachelospermi caulis Extract on Intestinal Barrier Function. Biological & pharmaceutical bulletin. 2015;38(11):1707-13.
- [4]. Ibne Mahbub MS, et al. Accelerated wound healing via ERK1/2 activation using tracheloside loaded multifunctional photocrosslinked ECM hybrid hydrogel. Advanced Composites and Hybrid Materials. 2026 Jul 1.
- [5]. Guo S, et al. Multi-target tracheloside and doxorubicin combined treatment of lung adenocarcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Sep;153:113392.
- [6]. Guo X, et al. Structural and theoretical basis for drug development targeting TMEM16A: Inhibition mechanism of tracheloside analogs. International Journal of Biological Macromolecules. 2024 Oct 1;277:134057.
- [7]. Kitamura Y, et al. Lack of significant inhibitory effects of a plant lignan tracheloside on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary carcinogenesis in female Sprague-Dawley rats. Cancer letters. 2003 Oct 28;200(2):133-9.
- [8]. Wang HF, et al. Tracheloside, the main constituent of the total lignan extract from Trachelospermi Caulis, inhibited rheumatoid arthritis via IL-17/MAPK signaling pathway. Fitoterapia. 2025 Jan 1;180:106311.
